Provide an acute coronary syndrome (NSTEMI/STEMI/UA) guide: recognition and initial…
- User
Provide an acute coronary syndrome (NSTEMI/STEMI/UA) guide: recognition and initial stabilization, diagnostic pathway (ECG/troponin), antithrombotic therapy and dosing, reperfusion strategies and timing, secondary prevention, discharge planning, and follow-up.
- Assistant
Acute Coronary Syndrome (ACS) Guide
ACS encompasses ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). This guide follows 2023 AHA/ACC guidelines. Always tailor to patient specifics; consult local protocols.
1. Recognition and Initial Stabilization
Clinical Recognition
- Symptoms: Retrosternal chest pain/pressure (>20 min, new/worsening), radiating to arm/jaw/neck; dyspnea, nausea, diaphoresis, fatigue. Atypical in women, elderly, diabetics (e.g., jaw pain, epigastric discomfort).
- Risk Factors: Age >55M/>65F, HTN, DM, smoking, dyslipidemia, family history, prior CAD.
- High-Risk Features: Hemodynamic instability, sustained VT, new heart failure, syncope.
Initial Stabilization (ABCDE Approach)
- Airway/Breathing: O2 if SpO2 <90% or respiratory distress (avoid routine O2).
- Circulation:
- IV access, continuous monitoring (ECG, BP, HR).
- Aspirin: 162-325 mg chewed stat (unless contraindicated).
- Nitroglycerin: 0.4 mg SL q5min x3 if ongoing pain, SBP >90 mmHg (avoid in RV infarct, recent PDE5i, severe AS).
- Morphine: 2-5 mg IV if pain persists (controversial; use sparingly).
- Disability/Exposure: Bed rest, warmth.
- Transfer: To PCI-capable center if STEMI.
2. Diagnostic Pathway
ECG (Door-to-ECG <10 min)
- STEMI: ≥1 mm ST-elevation in ≥2 contiguous leads (or new LBBB); posterior (V7-V9 ST-depression + elevation).
- NSTEMI/UA: ST-depression/T-wave inversion, normal, or nonspecific.
- Repeat ECG q15-30 min if initial nondiagnostic + ongoing pain.
Cardiac Biomarkers
Test Timing/Details Interpretation High-Sensitivity Troponin (hs-Tn) Stat + 1-3h serial (or 0/1h/3h algorithm) >99th %ile URL = MI if rise/fall + symptoms/ECG/echo changes. hs-Tn preferred for speed. CK-MB If troponin unavailable Less specific. - ACS Confirmed: Symptoms + ECG/Biochem changes.
- Risk Stratify NSTE-ACS: TIMI/GRACE score (high-risk: ≥3 TIMI = early invasive).
Echo if available: RWMA, EF, complications (MR, VSD, tamponade).
3. Antithrombotic Therapy and Dosing
All ACS: Dual Antiplatelet Therapy (DAPT) + anticoagulant.
Antiplatelet Agents
Agent Loading Dose Maintenance Dose Notes Aspirin 162-325 mg chewed 81 mg daily indefinitely All patients. P2Y12 Inhibitors - Ticagrelor (preferred) 180 mg 90 mg BID x12 mo (then 60 mg BID if PCI) Avoid in prior ICH; dyspnea common. - Prasugrel 60 mg 10 mg daily (5 mg if <60 kg or ≥75y) Avoid if prior TIA/stroke, age ≥75y. - Clopidogrel 600 mg 75 mg daily If ticagrelor/prasugrel CI; CYP2C19 test if high risk. - DAPT Duration: 12 mo post-ACS/PCI; extend if low bleed risk.
Anticoagulants (Upstream in NSTE-ACS; during PCI)
Agent Dose (ACS) Adjustments Duration UFH Bolus 60 U/kg IV (max 4000 U); inf 12 U/kg/h (max 1000 U/h) aPTT 1.5-2x control PCI or 48h Enoxaparin 1 mg/kg SC q12h 1 mg/kg q24h if CrCl <30 48h or hosp Bivalirudin 0.75 mg/kg bolus; 1.75 mg/kg/h inf CrCl adjust PCI only Fondaparinux 2.5 mg SC daily Avoid if CrCl <30 48h or discharge - Parenteral until PCI/revasc or 48h.
4. Reperfusion Strategies and Timing
STEMI (Primary Reperfusion Goal)
Strategy Timing (First Medical Contact) Preferred Population Primary PCI <90 min (door-to-balloon <90 min) All; radial access preferred. Fibrinolysis <30 min if PCI delay >120 min If PCI >120 min away; TNK-tPA 40 mg IV <100 kg. - Contraindications Active bleed, recent stroke/CVA, etc. - Transfer: If non-PCI center, <120 min to PCI.
- Rescue PCI if fibrinolysis failure (<90 min ST-res).
NSTE-ACS (Ischemia-Guided vs. Invasive)
Risk Strategy Timing High (GRACE >140, TIMI ≥3) Invasive (cath) <24h Intermediate Invasive <72h Low Conservative (meds ± noninvasive test) Discharge or outpatient - Glycoprotein IIb/IIIa (e.g., tirofiban) if high thrombus burden (rare now).
5. Secondary Prevention
Start in-hospital; optimize at discharge.
Therapy Class Agents/Targets Indications/All Patients Unless CI Antiplatelet DAPT as above All. Statin High-intensity (atorva 40-80 mg, rosuva 20-40 mg); LDL <70 mg/dL All. PCSK9i if LDL >70 on max statin. Beta-Blocker Metoprolol succ 25-50 mg BID; target HR 50-60 All (EF <40% lifelong). ACEI/ARB Lisinopril 5-40 mg; or losartan EF ≤40%, HTN, DM, CKD. Aldosterone Antag Spironolactone 25 mg EF ≤40% + DM or HF. SGLT2i/GLP1RA Empagliflozin/Dapagliflozin; semaglutide DM/CV risk. - Lifestyle: Smoking cessation, diet (Med), exercise (CR 36 sessions), BP <130/80, A1c <7%.
6. Discharge Planning
- Criteria: Hemodynamically stable, <24h rest angina, successful revasc, no arrhythmia/major complications.
- Education:
- Med adherence (pill box), symptoms to return for (worsening pain, SOB).
- Activity: Gradually increase; avoid heavy lifting x1-2 wk post-PCI.
- Diet: Low sat fat/salt; alcohol moderation.
- Meds at Discharge (table format as above).
- Cardiac Rehab Referral: All eligible.
- Devices: ICD if EF ≤35% >40 days post-MI.
7. Follow-Up
- Timing: 1-2 wk post-discharge (primary care/cardio); then 4-6 wk for echo/EF if indicated.
- Tests: Lipids 4-6 wk; echo if EF unknown; stress test if med Rx for NSTE.
- Long-Term: Annual flu vaccine; monitor for HF, recurrent ischemia.
- Dual Therapy Switch: Ticagrelor + riva/bro 1-3 mo post-PCI if high bleed risk.
Key Pearls: Time is muscle. Radial PCI reduces bleed. Multidisciplinary team. Individualize based on age/bleed risk (e.g., PRECISE-DAPT score). For updates, reference AHA/ACC or ESC guidelines. This is not medical advice—consult a clinician.